Department of Dermatology and Cutaneous Surgery, USF Health Morsani College of Medicine, Tampa, Florida.
Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus.
JAMA Dermatol. 2023 Feb 1;159(2):192-197. doi: 10.1001/jamadermatol.2022.5740.
Cutaneous T-cell lymphoma (CTCL) is a group of rare, complex cutaneous malignant neoplasms associated with significant disease burden on patients and the health care system. Currently, the population of patients with CTCL admitted to the hospital remains largely uncharacterized and poorly understood.
To characterize the clinical characteristics, course of hospitalization, and mortality outcomes of an inpatient CTCL cohort.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study reviewed medical records for adult patients (age ≥18 years) with a CTCL diagnosis per National Comprehensive Cancer Network guidelines admitted for inpatient hospitalization at 5 US academic medical centers with inpatient dermatology consult services and CTCL clinics between August 2016 and August 2020.
Patient demographics, clinical history and findings, hospitalization courses, and mortality outcomes.
A total of 79 hospitalized patients with CTCL were identified, including 52 (70.3%) men and 22 (29.7%) women, with a median (IQR) age at hospitalization of 62.9 (27-92) years. The majority of admitted patients with CTCL were White (65 patients [82.3%]), had disease classified as mycosis fungoides (48 patients [61.5%]), and had advanced-stage disease (≥IIB, 70 patients [89.7%]). Most hospitalizations were complicated by infection (45 patients [57.0%]) and required intravenous antibiotic therapy (45 patients [57.0%]). In-hospital mortality occurred in 6 patients (7.6%) and was associated with higher body mass index (36.5 vs 25.3), history of thromboembolic disease (50.0% vs 12.3%), and diagnosis of sepsis on admission (66.7% vs 20.5%). At 1-year postdischarge, 36 patients (49.3%) patients had died, and mortality was associated with history of solid organ cancers (27.8% vs 10.8%), wound care as the reason for dermatology consultation (58.3% vs 24.3%), and presence of large cell transformation (58.3% vs 22.9%).
The findings of this cohort study improve the understanding of hospitalized patients with CTCL and lend valuable insight into identifying factors associated with both in-hospital and long-term mortality outcomes. This refined understanding of the inpatient CTCL population provides a foundation for larger, more robust studies to identify causal risk factors associated with mortality, development of prognostic scoring systems to estimate the probability of hospital mortality. Overall, the findings may prompt physicians caring for patients with CTCL to implement preventive strategies to diminish hospitalization and improve clinical management across this unique disease spectrum.
皮肤 T 细胞淋巴瘤(CTCL)是一组罕见的、复杂的皮肤恶性肿瘤,给患者和医疗保健系统带来了巨大的疾病负担。目前,住院的 CTCL 患者人群在很大程度上仍未被充分描述和理解。
描述住院 CTCL 患者队列的临床特征、住院过程和死亡率结局。
设计、地点和参与者:这项多中心回顾性队列研究对 2016 年 8 月至 2020 年 8 月期间,在美国 5 所学术医疗中心住院的、患有 CTCL 的成年患者(年龄≥18 岁)的医疗记录进行了回顾,这些患者符合美国国家综合癌症网络指南中 CTCL 的诊断标准,且住院时需要皮肤科会诊服务和 CTCL 诊所。
患者人口统计学、临床病史和检查结果、住院过程和死亡率结局。
共确定了 79 例住院 CTCL 患者,其中 52 例(70.3%)为男性,22 例(29.7%)为女性,住院时的中位(IQR)年龄为 62.9(27-92)岁。大多数住院 CTCL 患者为白人(65 例[82.3%])、疾病分类为蕈样真菌病(48 例[61.5%])和晚期疾病(≥IIB,70 例[89.7%])。大多数住院治疗都因感染(45 例[57.0%])而变得复杂,并需要静脉用抗生素治疗(45 例[57.0%])。6 例(7.6%)患者发生院内死亡,与较高的体重指数(36.5 比 25.3)、血栓栓塞疾病史(50.0%比 12.3%)和入院时诊断为败血症(66.7%比 20.5%)有关。出院后 1 年时,36 例(49.3%)患者死亡,与实体器官癌史(27.8%比 10.8%)、皮肤科就诊的原因是伤口护理(58.3%比 24.3%)和大细胞转化存在(58.3%比 22.9%)有关。
这项队列研究的结果提高了对住院 CTCL 患者的认识,并深入了解与院内和长期死亡率结局相关的因素。对住院 CTCL 人群的这种细致理解为识别与死亡率相关的因果风险因素、制定估计住院死亡率概率的预后评分系统提供了基础。总的来说,这些发现可能促使治疗 CTCL 患者的医生实施预防策略,以减少住院治疗并改善整个独特疾病谱的临床管理。